Vitamin B12 is NOT prescribed as a treatment for myelodysplastic syndromes (MDS), but it must be checked and excluded as a cause of cytopenias before diagnosing MDS.
Critical Diagnostic Distinction
The primary role of vitamin B12 in MDS is diagnostic exclusion, not therapeutic intervention. The 2021 ESMO guidelines explicitly state that laboratory evaluation for MDS should include "vitamin B12 and folate concentrations" to "exclude the differential diagnoses of iron deficiency anaemia, haemolytic anaemia, vitamin B12 or folate deficiency" 1. This is a crucial step because B12 deficiency can mimic MDS with remarkable similarity.
Why B12 Testing is Essential Before MDS Diagnosis
The Mimicry Problem
Severe vitamin B12 deficiency can present with:
- Pancytopenia (low counts in all blood cell lines)
- Macrocytic anemia
- Bone marrow dysplasia that looks morphologically identical to MDS
- Even elevated blast counts that suggest MDS with excess blasts 2, 3
Multiple case reports demonstrate patients misdiagnosed with MDS who actually had B12 deficiency 4, 3, 5. These patients responded completely to B12 supplementation, avoiding unnecessary MDS treatments like hypomethylating agents 5.
Important Diagnostic Pitfall
Normal serum B12 levels do NOT rule out B12 deficiency in this context 4, 3. Studies show patients with "normal" B12 levels who still had functional B12 deficiency causing MDS-like presentations. When methylmalonic acid (MMA) and homocysteine levels were checked, they were elevated, confirming true B12 deficiency 3. After B12 supplementation, complete blood counts normalized within 7 days 4.
Treatment Recommendations for Confirmed MDS
Once MDS is definitively diagnosed (after excluding B12 deficiency), the 2021 ESMO guidelines provide clear treatment algorithms 1:
For Lower-Risk MDS:
- Erythropoiesis-stimulating agents (ESAs) for anemia [I, A]
- Lenalidomide for del(5q) with transfusion-dependent anemia [I, A]
- Luspatercept after ESA failure in MDS with ring sideroblasts [I, A]
For Higher-Risk MDS:
- Azacitidine for patients without major comorbidities [I, A]
- Allogeneic stem cell transplantation for eligible patients <70 years [I, A]
Vitamin supplementation (folate, vitamin B12, and pyridoxine) has seldom been rewarding in true MDS 6.
Clinical Algorithm
- Patient presents with cytopenias and suspected MDS
- Check vitamin B12 levels (and folate) as part of initial workup 1
- If B12 is low OR if clinical suspicion is high despite normal B12:
- Only proceed with MDS-specific treatment after definitively excluding B12 deficiency
Key Caveat
One case report suggests a patient with pernicious anemia later developed true MDS during B12 replacement therapy 7, indicating these can occasionally coexist. However, this is rare and doesn't change the fundamental principle: always exclude and correct B12 deficiency before diagnosing and treating MDS.